Spondyloarthritis & psoriatic arthritis
Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies
Authors' conclusion
This analysis of data from tofacitinib-treated patients with PsA demonstrated moderate agreement between the DAPSA and VLDA/MDA composite instruments.
Study context
- Population
- Tofacitinib-treated patients with PsA from two phase 3 studies (6 and 12 months' duration)2 phase 3 studies
- Comparison
- DAPSA-REM/DAPSA-LDA vs very low disease activity (VLDA)/MDA targets
- Outcome
- Agreement between achieving DAPSA (remission (REM) ≤4; Low disease activity (LDA) >4-≤14) and VLDA/MDA (7 or ≥5 of 7 criteria) targets
- Follow-up
- Months 1-6
Methodological detailsordered logistic regression, kappa tests
- Ordered logistic regression
- Kappa tests
Pooled result
As reported in the abstract
months 1 to 6
Moderate agreement (kappa)
0.41-0.60
Further pooled results
Baseline predictors of achieving targets · month 3
- Increased baseline disease activity associated with reduced likelihood of achieving DAPSA-REM/DAPSA-LDA or VLDA/MDA
Health Assessment Questionnaire-Disability Index (HAQ-DI) and SF-36 Physical Component Summary (PCS) change · month 6
- Achieving DAPSA-REM/DAPSA-LDA or VLDA/MDA associated with improved HAQ-DI and SF-36 PCS scores
Radiographic progression (modified Total Sharp Score (mTSS)) · month 12
- Achieving targets associated with slightly reduced radiographic progression
- Only
Original publication
Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies. Semin Arthritis Rheum. Published 13 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →